SynthesisBMC cancer2026
CDK4/6 inhibitors combined with fulvestrant for the treatment of HR+/HER2-advanced or metastatic breast cancer: a Bayesian network meta-analysis.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to assess the efficacy and safety of different CDK4/6 inhibitors combined with fulvestrant in treating HR+/HER2– advanced or metastatic breast cancer, using a Bayesian network meta-analysis.
methodsA comprehensive search was conducted across major medical databases, including PubMed, Web of Science, Cochrane Library, and Embase, to identify randomized controlled trials (RCTs) investigating the combination of CDK4/6 inhibitors and fulvestrant for HR+/HER2– advanced or metastatic breast cancer. The search encompassed studies published from database inception to Sep 10, 2025. Relevant studies were screened, data extracted, and risk of bias evaluated. A Bayesian network meta-analysis was performed using R software (version 4.5.1).
resultsTen randomized controlled trials involving seven CDK4/6 inhibitors combined with fulvestrant were included. All regimens significantly improved progression-free survival (PFS) versus placebo + fulvestrant, and tibremciclib + fulvestrant ranked first among all regimens (HR = 0.37, 95% CrI 0.27–0.52; SUCRA = 89.26%), followed by dalpiciclib (HR = 0.42) and lerociclib (HR = 0.45). Abemaciclib + fulvestrant and palbociclib + fulvestrant demonstrated favorable overall survival (OS) improvements (HR = 0.76 and 0.79, respectively), consistent with pivotal trial evidence. For objective response rate (ORR), tibremciclib + fulvestrant ranked highest (RR = 4.0, 95% CrI 1.2–15.0), while clinical benefit rate (CBR) and quality of life (QoL) showed no statistically significant improvement compared with placebo. In safety analyses, abemaciclib + fulvestrant was associated with higher overall adverse events (RR = 1.16, 95% CrI 1.02–1.34), and bireociclib, dalpiciclib, and lerociclib showed increased risks of grade 3–4 events. Bireociclib and abemaciclib regimens also had higher rates of serious adverse events and treatment discontinuation.
conclusionsAll CDK4/6 inhibitors combined with fulvestrant significantly improve progression-free survival in HR+/HER2 − advanced breast cancer, with abemaciclib and palbociclib also showing overall survival benefits. Tibremciclib plus fulvestrant showed relatively higher efficacy, demonstrating moderately superior performance to other regimens, while abemaciclib plus fulvestrant was associated with a higher incidence of treatment-related adverse events. These findings confirm the class effect of CDK4/6 inhibition and highlight the need to balance efficacy with tolerability. Future biomarker-informed and real-world studies are warranted to optimize treatment sequencing and support personalized therapeutic decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.